Amryt Pharma (Amryt Pharma) Dividend Payout Ratio : 0.00 (As of Sep. 2022)

View and export this data going back to 2019. Start your Free Trial

What is Amryt Pharma Dividend Payout Ratio?

Amryt Pharma's dividend payout ratio for the months ended in Sep. 2022 was 0.00.

The historical rank and industry rank for Amryt Pharma's Dividend Payout Ratio or its related term are showing as below:

AMYT's Dividend Payout Ratio is not ranked ^*
in the Drug Manufacturers industry.
Industry Median: 0.34
* Ranked among companies with meaningful Dividend Payout Ratio only.

As of today (2024-06-07), the Dividend Yield % of Amryt Pharma is 0.00%.

Amryt Pharma's Dividends per Share for the months ended in Sep. 2022 was $0.00.

The growth rate is calculated with least square regression.

For more information regarding to dividend, please check our Dividend Page.

Amryt Pharma Dividend Payout Ratio Historical Data

The historical data trend for Amryt Pharma's Dividend Payout Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Amryt Pharma Dividend Payout Ratio Chart

Amryt Pharma Annual Data

Trend

Mar12

Mar13

Mar14

Mar15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dividend Payout Ratio

Get a 7-Day Free Trial

Amryt Pharma Quarterly Data
	Dec16	Jun17	Dec17	Jun18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22
Dividend Payout Ratio	Get a 7-Day Free Trial															-	-	-	-	-

Competitive Comparison of Amryt Pharma's Dividend Payout Ratio

For the Drug Manufacturers - Specialty & Generic subindustry, Amryt Pharma's Dividend Payout Ratio, along with its competitors' market caps and Dividend Payout Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Amryt Pharma's Dividend Payout Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Amryt Pharma's Dividend Payout Ratio distribution charts can be found below:

* The bar in red indicates where Amryt Pharma's Dividend Payout Ratio falls into.

Amryt Pharma Dividend Payout Ratio Calculation

Dividend payout ratio measures the percentage of the company's earnings paid out as dividends.

Amryt Pharma's Dividend Payout Ratio for the fiscal year that ended in Dec. 2021 is calculated as

Dividend Payout Ratio	=	Dividends per Share (A: Dec. 2021 )	/	EPS without NRI (A: Dec. 2021 )
	=	0	/	0.02
	=	0.00

Amryt Pharma's Dividend Payout Ratio for the quarter that ended in Sep. 2022 is calculated as

Dividend Payout Ratio	=	Dividends per Share (Q: Sep. 2022 )	/	EPS without NRI (Q: Sep. 2022 )
	=	0	/	-0.3
	=	N/A

Amryt Pharma (NAS:AMYT) Dividend Payout Ratio Explanation

In dividends investing, Payout Ratio and Dividend Growth Rate are the two most important variables for consideration. A lower payout ratio may indicate that the company has more room to increase its dividends.

Amryt Pharma Dividend Payout Ratio Related Terms

Thank you for viewing the detailed overview of Amryt Pharma's Dividend Payout Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.

Amryt Pharma (Amryt Pharma) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Amryt Pharma PLC (NAS:AMYT) » Definitions » Dividend Payout Ratio

Comparable Companies

Traded in Other Exchanges

N/A

Address

196 High Road, Dept 920A, Wood Green, London, GBR, N22 8HH

Website

http://www.amrytpharma.com

Amryt Pharma PLC is a specialty pharmaceutical company. It is focused on developing and delivering new treatments to help improve the lives of patients with rare or orphan diseases. It holds an exclusive license to sell Lojuxta (lomitapide) for adults, across the European Union and other territories including the Middle East, North Africa, Turkey and Israel. Lojuxta is used to treat a rare life-threatening disease called Homozygous Familial Hypercholesterolemia. Myalept (metreleptin) is an adjunct to diet as replacement therapy to treat the complications of leptin deficiency in patients. It derives most of the revenue from the European Economic Area (EEA).